Conmed Corp. (NASDAQ:CNMD) EVP Daniel Jonas sold 2,555 shares of the firm’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $40.40, for a total value of $103,222.00. Following the completion of the transaction, the executive vice president now directly owns 20,120 shares in the company, valued at $812,848. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Daniel Jonas also recently made the following trade(s):

  • On Tuesday, November 8th, Daniel Jonas sold 1,500 shares of Conmed Corp. stock. The shares were sold at an average price of $41.78, for a total value of $62,670.00.

Conmed Corp. (NASDAQ:CNMD) opened at 42.65 on Thursday. The company has a market capitalization of $1.19 billion, a P/E ratio of 76.16 and a beta of 0.81. Conmed Corp. has a 12 month low of $35.51 and a 12 month high of $50.16. The firm has a 50-day moving average price of $39.87 and a 200 day moving average price of $41.89.

Conmed Corp. (NASDAQ:CNMD) last announced its quarterly earnings results on Thursday, October 27th. The medical technology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.01. Conmed Corp. had a return on equity of 8.26% and a net margin of 2.11%. The company earned $184.79 million during the quarter, compared to the consensus estimate of $180.13 million. During the same period in the prior year, the company earned $0.45 earnings per share. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. Analysts expect that Conmed Corp. will post $1.87 EPS for the current year.

Insider Buying and Selling by Quarter for Conmed Corp. (NASDAQ:CNMD)

A number of brokerages recently weighed in on CNMD. Leerink Swann reissued a “market perform” rating and issued a $43.00 price objective (down from $47.00) on shares of Conmed Corp. in a research note on Friday, October 28th. Zacks Investment Research raised Conmed Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, September 27th.

Several large investors have recently made changes to their positions in CNMD. Scopia Capital Management LP acquired a new stake in shares of Conmed Corp. during the first quarter valued at about $99,828,000. Dimensional Fund Advisors LP boosted its position in Conmed Corp. by 1.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,350,620 shares of the medical technology company’s stock valued at $112,193,000 after buying an additional 38,595 shares in the last quarter. BlackRock Fund Advisors boosted its position in Conmed Corp. by 5.9% in the third quarter. BlackRock Fund Advisors now owns 1,784,214 shares of the medical technology company’s stock valued at $71,476,000 after buying an additional 99,778 shares in the last quarter. Victory Capital Management Inc. boosted its position in Conmed Corp. by 70.7% in the third quarter. Victory Capital Management Inc. now owns 1,679,961 shares of the medical technology company’s stock valued at $67,299,000 after buying an additional 696,008 shares in the last quarter. Finally, Champlain Investment Partners LLC boosted its position in Conmed Corp. by 61.1% in the second quarter. Champlain Investment Partners LLC now owns 1,465,640 shares of the medical technology company’s stock valued at $69,955,000 after buying an additional 556,060 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

Conmed Corp. Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Its products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

5 Day Chart for NASDAQ:CNMD

Receive News & Stock Ratings for Conmed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conmed Corp. and related stocks with our FREE daily email newsletter.